These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17761674)

  • 1. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.
    Dreux M; Boson B; Ricard-Blum S; Molle J; Lavillette D; Bartosch B; Pécheur EI; Cosset FL
    J Biol Chem; 2007 Nov; 282(44):32357-69. PubMed ID: 17761674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.
    Catanese MT; Ansuini H; Graziani R; Huby T; Moreau M; Ball JK; Paonessa G; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2010 Jan; 84(1):34-43. PubMed ID: 19828610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.
    Voisset C; Callens N; Blanchard E; Op De Beeck A; Dubuisson J; Vu-Dac N
    J Biol Chem; 2005 Mar; 280(9):7793-9. PubMed ID: 15632171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
    Bankwitz D; Vieyres G; Hueging K; Bitzegeio J; Doepke M; Chhatwal P; Haid S; Catanese MT; Zeisel MB; Nicosia A; Baumert TF; Kaderali L; Pietschmann T
    J Virol; 2014 Nov; 88(21):12644-55. PubMed ID: 25142595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
    Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL
    J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.
    Dao Thi VL; Granier C; Zeisel MB; Guérin M; Mancip J; Granio O; Penin F; Lavillette D; Bartenschlager R; Baumert TF; Cosset FL; Dreux M
    J Biol Chem; 2012 Sep; 287(37):31242-57. PubMed ID: 22767607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
    Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.
    Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B
    PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.
    Calattini S; Fusil F; Mancip J; Dao Thi VL; Granier C; Gadot N; Scoazec JY; Zeisel MB; Baumert TF; Lavillette D; Dreux M; Cosset FL
    J Biol Chem; 2015 Sep; 290(38):23173-87. PubMed ID: 26224633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation.
    Dao Thi VL; Dreux M; Cosset FL
    Expert Rev Mol Med; 2011 Apr; 13():e13. PubMed ID: 21489334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.
    Gao R; Gao W; Xu G; Xu J; Ren H
    World J Gastroenterol; 2017 Jul; 23(28):5158-5166. PubMed ID: 28811710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
    Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
    J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
    Perrault M; Pécheur EI
    Biochem J; 2009 Oct; 423(3):303-14. PubMed ID: 19807698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.
    Zahid MN; Turek M; Xiao F; Thi VL; Guérin M; Fofana I; Bachellier P; Thompson J; Delang L; Neyts J; Bankwitz D; Pietschmann T; Dreux M; Cosset FL; Grunert F; Baumert TF; Zeisel MB
    Hepatology; 2013 Feb; 57(2):492-504. PubMed ID: 23081796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-I reduces cholesteryl esters selective uptake from LDL and HDL by binding to HepG2 cells and lipoproteins.
    Krasteva V; Brodeur MR; Tremblay FL; Falstrault L; Brissette L
    Biochim Biophys Acta; 2010 Jan; 1801(1):42-8. PubMed ID: 19761869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    Denolly S; Granier C; Fontaine N; Pozzetto B; Bourlet T; Guérin M; Cosset FL
    J Hepatol; 2019 Apr; 70(4):626-638. PubMed ID: 30553840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.
    Syder AJ; Lee H; Zeisel MB; Grove J; Soulier E; Macdonald J; Chow S; Chang J; Baumert TF; McKeating JA; McKelvy J; Wong-Staal F
    J Hepatol; 2011 Jan; 54(1):48-55. PubMed ID: 20932595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
    Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J
    J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
    Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
    Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.